Systemic sclerosis refractory disease: From the skin to the heart

Autoimmunity Reviews

Volumn 10, Issue 11, 2011, Pages 693-701

  Almeida, Isabel ^a,b   Faria, Raquel ^a   Vita, Pedro ^a,b   Vasconcelos, Carlos ^a  

^a HOSPITAL DE SANTO ANTÓNIO   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

Author keywords

Refractory autoimmune disease; Refractory scleroderma; Systemic sclerosis

Indexed keywords

ABATACEPT; ACETYLSALICYLIC ACID; AMBRISENTAN; ATORVASTATIN; AZATHIOPRINE; BOSENTAN; BOTULINUM TOXIN; CALCIUM CHANNEL BLOCKING AGENT; CISAPRIDE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUOXETINE; GLYCERYL TRINITRATE; ILOPROST; IMATINIB; IMMUNOGLOBULIN; METHOTREXATE; MQX 503; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NIFEDIPINE; OCTREOTIDE; PENICILLAMINE; PENTOXIFYLLINE; PREDNISOLONE; RITUXIMAB; SILDENAFIL; TADALAFIL; THYMOCYTE ANTIBODY; TOCILIZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; COMORBIDITY; DIGITAL ULCER; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; GASTROINTESTINAL DISEASE; HEART ARRHYTHMIA; HEART CATHETERIZATION; HEART DISEASE; HUMAN; INTERSTITIAL LUNG DISEASE; MUSCULOSKELETAL DISEASE; MYOSITIS; PROGNOSIS; PULMONARY HYPERTENSION; RAYNAUD PHENOMENON; REHABILITATION CARE; REVIEW; SCORING SYSTEM; SYMPATHECTOMY; SYSTEMIC SCLEROSIS; TREATMENT RESPONSE; ULCER; WHOLE BODY RADIATION;

ANTIFIBRINOLYTIC AGENTS; CLINICAL TRIALS AS TOPIC; CONNECTIVE TISSUE; DISEASE PROGRESSION; DRUG RESISTANCE; FIBROSIS; HUMANS; HYPERTENSION, PULMONARY; IMMUNOLOGIC FACTORS; MICROVESSELS; RECURRENCE; RENAL INSUFFICIENCY; SCLERODERMA, SYSTEMIC; SKIN ULCER; STEM CELL TRANSPLANTATION;

EID: 80052267725     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2011.04.025     Document Type: Review

References (82)

1. Mouthon L., Allanore Y., Cabane J., Hachulla E. Sclérodermie systemique. Traité des maladies et syndromes systémiques 2009, 410-470. Medicine-Science Flammarion. 5 Edition. L. Guillevin, O. Meyer, J. Sibilia (Eds.).
2. Steen V.D., Costantino J.P., Chapiro A.P., Medsger T.A. Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors. Ann Intern Med 1990, 113:352-357.
3. McLaughlin V.V. Survival in patients with pulmonary arterial hypertension treated with first-line bosenta. Eur J Clin Invest 2006, 36(Suppl. 3):10-15.
4. Williams M.H., Das C., Handler C.E., Akram M.R., Davar J., Denton C.P., et al. Systemic sclerosis associated pulmonary hypertension: improved survival in the current era. Heart 2006, 92:926-932.
5. Wigley F.M. When is scleroderma really scleroderma?. J Rheumatol 2001, 28(7):1471-1473.
6. Tyndall A. Autologous haematopoietic stem cell transplants for autoimmune disease - feasibility and transplant-related mortality. Bone Marrow Transplant 1999, 24:729-734.
7. Gabrielli A., Avvedimento E.V., Krieg T. Scleroderma. N Engl J Med 2009, 360:1989-2003.
8. Kowal-Bielecka O., Landewé R., Avouac J., Chwiesko S., Miniati I., Czirjak L., et al. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group EUSTAR. Ann Rheum Dis 2009, 68(5):620-628.
9. Medsger T.A., Bombardieri S., Czirjak L., Scorza R., Della Rossa A., Bencivelli W. Assessment of disease severity and prognosis. Clin Exp Rheumatol 2008, 21(3):S42-S46.
10. Hudson M., Steele R., Canadian Scleroderma Research Group (CSRG), Baron M. Update on indices of disease activity in systemic sclerosis. Semin Arthritis Rheum 2007, 37:93-98.
11. Nihtyanova S.I., Denton C.P. Current approaches to the management of early active diffuse scleroderma skin disease. Rheum Dis Clin North Am 2008, 34(1):161-179.
12. Poole J. Musculoskeletal rehabilitation in the person with scleroderma. Curr Opin Rheumatol 2010, 22:205-212.
13. Clements P.J., Lachenbruch P., Siebold J., White B., Weiner S., Martin R., et al. Inter- and intraobserver variability of total skin thickness core (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995, 22:1281-1285.
14. Furst D.E., Clements P.J., Steen V.D., Medsger T.A., Masi A.T., D'Angelo W.A., et al. The modified Rodnan skin score is an accurate reflection of skin biopsy thickness in systemic sclerosis. J Rheumatol 1998, 25:84-88.
15. Akesson A., Fiori G., Krieg T., van den Hoogen F.H., Seibold J.R. Assessment of skin, joint, tendon and muscle involvement. Clin Exp Rheumatol 2003, 21(Suppl. 29):S5-S8.
16. Stratton R.J., Wilson H., Black C.M. Pilot study of anti-thymocyte globulin plus mycophenolate mofetil in recent-onset diffuse scleroderma. Rheumatology (Oxford) 2001, 40(1):84-88.
17. Le E.N., Wigley F.M., Shah A.A., Boin F., Hummers L.K. Long-term experience of mycophenolate mofetil for treatment of diffuse cutaneous systemic sclerosis. Ann Rheum Dis 2011, 70(6):1104-1107.
18. Derk C.T., Grace E., Shenin M., Naik M., Schulz S., Xiong W. A prospective open-label study of mycophenolate mofetil for the treatment of diffuse systemic sclerosis. Rheumatology 2009, 48(12):1595-1599.
19. Paone C., Chiarolanza I., Cuomo G., Ruocco L., Vettori S., Menegozzo M., et al. Twelve-month azathioprine as maintainance therapy in early diffuse systemic sclerosis patients treated for 1-year with low-dose cyclophosphamide pulse therapy. Clin Exp Rheumatol 2007, 25:613-616.
20. Smith V.P., Praet J.T.V., Vandooren B.R.M., Van der Cruyssen B., Naeyaert J.M., Decuman S., et al. Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study. Ann Rheum Dis 2010, 69(1):193-197.
21. Daoussis D., Liossis S.N.C., Tsamandas A.C., Kalogeropoulou C., Kazantzi A., Sirinian C., et al. Experience with rituximab in scleroderma: results from a 1-year, proof-of principle study. Rheumatology 2010, 49:271-280.
22. Sfikakis P.P., Gorgoulis V.G., Katsiari C.G., Evangelou K., Kostopoulos C., Black C.M. Imatinib for the treatment of refractory, diffuse systemic sclerosis. Rheumatology 2008, 47:735-737.
23. Gordon J.K., Spiera R.F. Targeting tyrosine kinases: a novel therapeutic strategy for systemic sclerosis. Curr Opin Rheumatol 2010, 22(69):690-695.
24. Spiera R.F., Gordon J.K., Mersten J.N., Magro C.M., Mehta M., Wildman H.F., et al. Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial. Ann Rheum Dis 2011, 70(6):1003-1009.
25. Ogata A., Kawai M., Morishima A., Ogawa M., Ishii T., Kuwahara Y., et al. Clinical effects of tocilizumab, a humanized anti-interleukin-6 receptor antibody on patients with autoimmune and inflammatory diseases. Ann Rheum Dis 2010, 69(Suppl. 3):664. [Abstract].
26. Shima Y., Kuwahara Y., Murota H., Kitaba S., Kawai M., Hirano T., et al. The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab. Rheumatology 2010, 49(12):2408-2412.
27. Ong V.H., Denton C.P. Innovative therapies for systemic sclerosis. Curr Opin Rheumatol 2010, 22(3):264-272.
28. Sunderkötter C., Herrgott I., Brückner C., Moinzadeh P., Pfeiffer C., Gerss J., et al. Comparison of patients with and without digital ulcers in systemic sclerosis: detection of possible risk factors. Br J Dermatol 2009, 160(4):835-843.
29. Nihtyanova S.I., Brough G.M., Black C.M., Denton C.P. Clinical burden of digital vasculopathy in limited and diffuse cutaneous systemic sclerosis. Ann Rheum Dis 2008, 67(1):120-123.
30. Merkel P.A., Herlyn K., Martin R.W., Anderson J.J., Mayes M.D., Bell P., et al. Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon. Arthritis Rheum 2002, 46(9):2410-2420.
31. Caramaschi P. Scleroderma patients nailfold videocapillaroscopic patterns are associated with disease subset and disease severity. Rheumatology 2007, 46:1566-1569.
32. Sebastini M., Manfredi A., Colaci M., Giuggioli D., La Sala R., Elkhaldi N., et al. Correlazione di uno score quantitative capillaroscopico con lo sviluppo di ulcere ischemiche digitali nei pazienti com sclerosi sistémica. Reumatismo 2008, 60(3):199-205.
33. Herrick A. Diagnosis and management of scleroderma peripheral vascular disease. Rheum Dis Clin North Am 2008, 24:89-114.
34. Belch J.J., Hill A. Evening primrose oil and borage oil in rheumatologic conditions. Am J Clin Nutr 2000, 71(S1):S352-S356.
35. Garcia-Carrasco M., Jiménez-Hernández M., Escárcega R.O., Mendoza-Pinto C., Pardo-Santos R., Levy R., et al. Treatment of Raynaud's phenomenon. Autoimmun Rev 2008, 8(1):62-68.
36. Fries R., Shariat K., von Wilmowsky H., Böhm M. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. Circulation 2005, 112(19):2980-2985.
37. Chung L., Shapiro L., Fiorentino D., Baron M., Shanahan J., Sule S., et al. MQX-503, a novel formulation of nitroglycerin, improves the severity of Raynaud's phenomenon: a randomized, controlled trial. Arthritis Rheum 2009, 60(3):870-877.
38. Bogoch E.R., Gross D.K. Surgery of the hand in patients with systemic sclerosis: outcomes and considerations. J Rheumatol 2005, 32:642-648.
39. Yee A.M.F., Hotchkiss R.N., Paget S.A. Adventitial stripping: a digit saving procedure in refractory Raynaud's phenomena. J Rheumatol 1998, 25:269-276.
40. Steen V.D., Medsger T.A. The palpable tendon friction rub: an important physical examination finding in patients with systemic sclerosis. Arthritis Rheum 1997, 40(6):1146-1151.
41. Torok K.S., Baker N.A., Lucas M., Baker N.A., Lucas M., Domsic R.T., et al. Reliability and validity of the delta finger-to-palm (FTP), a new measure of finger range of motion in systemic sclerosis. Clin Exp Rheumatol 2010, 28(Suppl. 58):S28-S36.
42. Trang G., Steele R., Baron M., Hudson M. Corticosteroids and the risk of scleroderma renal crisis: a systematic review. Rheumatol Int 2010, [Electronic publication ahead of print], doi:10.1007/s00296-010-1697-6.
43. Sjogren R.W. Gastrointestinal disorders in scleroderma. Arthritis Rheum 1994, 37:1265-1282.
44. Clements P.J., Becvar R., Drosos A.A., Ghattas L., Gabrielli A. Assessment of gastrointestinal involvement. Clin Exp Rheumatol 2003, 21:S15-S18.
45. Nikou G.C., Toumpanakis C., Katsiari C., Charalambopoulos D., Sfikakis P.P. Treatment of small intestinal disease in systemic sclerosis with octreotide: a prospective study in seven patients. J Clin Rheumatol 2007, 13(3):119-123.
46. Soudah H.C., Hasler W.L., Owyang C. Effect of octreotide on intestinal motility and bacterial overgrowth in scleroderma. N Engl J Med 1991, 325:1461-1467.
47. Tang D.M., Friedenberg F.K. Gastroparesis: approach, diagnostic evaluation, and management. Dis Mon 2011, 57(2):74-101.
48. Steen V.D. Scleroderma renal crisis. Rheum Dis Clin North Am 2003, 29:315-333.
49. Steen V.D. The kidney in systemic sclerosis. The kidney in systemic autoimmune diseases 2008, 363-381. Elsevier, Amsterdam. J.C. Mason, C.D. Pusey (Eds.).
50. De Marco P.J., Weisman M.H., Seibold J.R., Furst D.E., Wong W.K., Hurwitz E.L., et al. Predictors and outcomes of scleroderma renal crisis. Arthritis Rheum 2002, 46(11):2983-2989.
51. Denton C.P., Lapadula G., Mouthon L., Müller-Ladner U. Renal complications and scleroderma renal crisis. Rheumatology 2009, 48:iii32-iii35.
52. Varga J. Overview of the clinical manifestations of systemic sclerosis (scleroderma) in adults, UpToDate 19.1 2011.
53. Steen V.D., Costantino J.P., Shapiro A.P., Medsger T.A. Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors. Ann Intern Med 1990, 113(5):352-357.
54. Arad U., Balbir-Gurman A., Doenyas-Barak K., Amit-Vazina M., Caspi D., Elkayam O. Anti-neutrophil antibody associated vasculitis in systemic sclerosis. Semin Arthritis Rheum 2011 Jan 28, [Electronic publication ahead of print], doi:10.1016/j.semarthrit.2010.11.001.
55. Rho Y.H., Choi S.J., Lee Y.H., Ji J.D., Song G.G. Scleroderma associated with ANCA-associated vasculitis. Rheumatol Int 2006, 26:369-375.
56. Sweiss N.J., Hushaw L., Thenappan T., Sawaqed R., Machado R.F., Patel A.R., et al. Diagnosis and management of pulmonary hypertension in systemic sclerosis. Curr Rheumatol Rep 2010, 12(1):8-18.
57. Avouac J., Airò P., Meune C., Beretta L., Dieude P., Caramaschi P., et al. Prevalence of pulmonary hypertension in systemic sclerosis in European Caucasians and meta-analysis of 5 studies. J Rheumatol 2010, 37(11):2290-2298.
58. Black C.M. Pulmonary arterial hypertension: are we doing enough to identify systemic sclerosis patients at high risk of this rare condition?. Rheumatology 2005, 44:141-142.
59. Matucci-Cerinic M., D'Angelo S., Denton C.P., Vlachoyiannopoulos P., Silver R. Assessment of lung involvement. Clin Exp Rheumatol 2003, 21(Suppl. 29):S19-S23.
60. Galie N., Hoeper M.M., Humbert M., Torbicki A., Vachiery J.L., Barbera J.A., et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2009, 30:2493-2537.
61. Lavelle A., Sugrue R., Lawler G., Mulligan N., Kelleher B., Murphy D.M., et al. Sitaxentan-induced hepatic failure in two patients with pulmonary arterial hypertension. ERJ 2009, 34(3):770-771.
62. Mathai S.C., Hassoun P.M. Therapy for pulmonary arterial hypertension associated with systemic sclerosis. Curr Opin Rheumatol 2009, 21(6):642-648.
63. Sabnani I., Zucker M.J., Rosenstein E.D., Baran D.A., Arroyo L.H., Tsang P., et al. A novel therapeutic approach to the treatment of scleroderma-associated pulmonary complications: safety and efficacy of combination therapy with imatinib and cyclophosphamide. Rheumatology 2009, 48:49-52.
64. Tyndall A., Matucci-Cerinic M., Muller-Ladner U. Future targets in the management of systemic sclerosis. Rheumatology 2009, 48:iii49-iii53.
65. Denton C.P., Black C.M. Pulmonary arterial hypertension in connective tissue disease. Pulmonary involvement in systemic autoimmune diseases 2004, 47-62. Elsevier, Amsterdam. A.U. Wells, C.P. Denton (Eds.).
66. Goh N.S., DuBois R.M. Interstitial disease in systemic sclerosis. Pulmonary involvement in systemic autoimmune diseases 2004, 181-207. Elsevier, Amsterdam. A.U. Wells, C.P. Denton (Eds.).
67. Simeón-Aznar C.P., Fonollosa-Plá V., Tolosa-Vilella C., Selva-O Callaghan A., Solans-Laqué R., Palliza E., et al. Intravenous cyclophosphamide pulse therapy in the treatment of systemic sclerosis-related interstitial lung disease: a long term study. Open Respir Med J 2008, 2:39-45.
68. Goh N.S., Desai S.R., Veeraraghavan S., Hansell D.M., Copley S.J., Maher T.M., et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 2008, 177(11):1248-1254.
69. Vargas J. Prognosis and treatment of interstitial lung disease in systemic sclerosis (scleroderma), UpToDate 19.1 2011.
70. Tashkin D.P., Elashoff R., Clements P.J., Goldin J., Roth M.D., Furst D.E., et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006, 354(25):2655-2666.
71. Hoyles R.K., Ellis R.W., Wellsbury J., Lees B., Newlands P., Goh N.S., et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 2006, 54(12):3962-3970.
72. Gerbino A.J., Goss C.H., Molitor J.A. Effect of mycophenolate mofetil on pulmonary function in scleroderma-associated interstitial lung disease. Chest 2008, 133(2):455-460.
73. Zamora A.C., Wolters P.J., Collard H.R., Connolly M.K., Elicker B.M., Webb W.R., et al. Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease. Respir Med 2008, 102(1):150-155.
74. Liossis S.N., Bounas A., Andonopoulos A.P. Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease. Rheumatology 2006, 45(8):1005-1008.
75. Vanthuyne M., Blockmans D., Westhovens R., Roufosse F., Cogan E., Coche E., et al. A pilot study of mycophenolate mofetil combined to intravenous methylprednisolone pulses and oral low-dose glucocorticoids in severe early systemic sclerosis. Clin Exp Rheumatol 2007, 25(2):287-292.
76. Nihtyanova S.I., Brough G.M., Black C.M., Denton C.P. Mycophenolate mofetil in diffuse cutaneous systemic sclerosis - a retrospective analysis. Rheumatology 2007, 46(3):442-445.
77. Dheda K., Lalloo U.G., Cassim B., Mody G.M. Experience with azathioprine in systemic sclerosis associated with interstitial lung disease. Clin Rheumatol 2004, 23(4):306-309.
78. Nadashkevich O., Davis P., Fritzler M., Kovalenko W. A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis. Clin Rheumatol 2006, 25(2):205-212.
79. Champion H.C. The heart in scleroderma. Rheum Dis Clin North Am 2008, 34(1):181-viii.
80. Ferri C., Emdin M., Nielsen H., Bruhlmann P. Assessment of heart involvement. Clin Exp Rheumatol 2003, 21(Suppl. 29):S24-S28.
81. Allanore Y., Meune C. Primary myocardial involvement in systemic sclerosis: evidence for a microvascular origin. Clin Exp Rheumatol 2010, 28(Suppl. 62):S48-S53.
82. Poanta L., Dadu R., Tiboc C., Rednic S., Dumitrascu D. Systolic and diastolic function in patients with systemic sclerosis. Eur J Intern Med 2009, 20:378-382.